

LONDON  
SCHOOL of  
HYGIENE  
& TROPICAL  
MEDICINE



LSHTM Research Online

Fasanelli, F; Baglietto, L; Ponzi, E; Guida, F; Campanella, G; Johansson, M; Grankvist, K; Johansson, M; Assumma, MB; Naccarati, A; +16 more... Chadeau-Hyam, M; Ala, U; Faltus, C; Kaaks, R; Risch, A; De Stavola, B; Hodge, A; Giles, GG; Southey, MC; Relton, CL; Haycock, PC; Lund, E; Polidoro, S; Sandanger, TM; Severi, G; Vineis, P; (2015) Hypomethylation of smoking-related genes is associated with future lung cancer in four prospective cohorts. *Nature communications*, 6. p. 10192. ISSN 2041-1723 DOI: <https://doi.org/10.1038/ncomms10192>

Downloaded from: <http://researchonline.lshtm.ac.uk/2478661/>

DOI: <https://doi.org/10.1038/ncomms10192>

**Usage Guidelines:**

Please refer to usage guidelines at <https://researchonline.lshtm.ac.uk/policies.html> or alternatively contact [researchonline@lshtm.ac.uk](mailto:researchonline@lshtm.ac.uk).

Available under license: <http://creativecommons.org/licenses/by/2.5/>

<https://researchonline.lshtm.ac.uk>

Probe Name	Gene Name	Information	References
cg05575921 cg21161138	<i>AHRR</i>	<i>AHRR</i> mediates dioxin toxicity and is involved in regulation of cell growth and differentiation.	Zudaire E et al. <i>The aryl hydrocarbon receptor repressor is a putative tumor suppressor gene in multiple human cancers.</i>
cg03636183	<i>F2RL3</i>	<i>F2RL3</i> codes for the thrombin PAR-4 The function of PAR-4 is not fully clear yet but there is emerging evidence that it might be involved in the pathophysiology of several malignant tumors including lung cancer	Zhang Y et al. <i>F2RL3 methylation, lung cancer incidence and mortality.</i>
cg21566642 cg01940273 cg05951221		the closest gene is <i>ALPPL2</i> <i>ALPPL2</i> is a protein coding gene whose expression is strongly correlated with that of Heme Oxygenase-1 gene (it is expressed in many cancers and promotes growth and survival of neoplastic cells)	Tauber S et al. <i>Transcriptome analysis of human cancer reveals a functional role of heme oxygenase-1 in tumor cell adhesion.</i>
cg06126421		the closest gene is <i>FLOT1</i> <i>FLOT1</i> seems to have a role in non-small cell lung cancer tumorigenesis	Li H et al. <i>Abnormal expression of FLOT1 correlates with tumor progression and poor survival in patients with non-small cell lung cancer.</i>
cg25305703	<i>CASC21</i>	<i>CASC21</i> (cancer susceptibility candidate 21) has an oncogenic function	Kim T et al. <i>Long-range interaction and correlation between MYC enhancer and oncogenic long noncoding RNA CARLo-5</i>
cg02451831	<i>KIAA0087</i>	<i>KIAA0087</i> is a RNA Gene, and belongs to non coding RNA class currently no evidence of involvement in cancer tumorigenesis	
cg04884171	<i>BOLA2</i>	<i>BOLA2</i> encodes the BolA-like protein 2; this protein is conserved from prokaryotes to eukaryotes and seems to be involved in cell proliferation or cell-cycle regulation	Hunecke D et al. <i>MYC-regulated genes involved in liver cell dysplasia identified in a transgenic model of liver cancer</i>
cg03898802	<i>DOPEY2</i>	<i>DOPEY2</i> is a protein coding gene currently no evidence of involvement in cancer tumorigenesis	

**Supplementary Table 1** - Main information about involvement in cancer pathways for the top-ranked CpGs found after the locus-by-locus risk analysis in NOWAC data (discovery set).

		<b>ca</b>	<b>co</b>	<b>OR for 1 SD</b>
<b><i>cg05575921-AHRR</i></b>	all	125	125	0.37(0.31-0.54)
	time to diagnosis <5 years	84	125	0.20(0.10-0.37)
	time to diagnosis >=5 years	41	125	0.42(0.30-0.56)
		<b>heterogeneity</b>		p=0.021
<b><i>cg03636183-F2RL3</i></b>	all	125	125	0.40(0.31-0.56)
	time to diagnosis <5 years	84	125	0.32(0.19-0.54)
	time to diagnosis >=5 years	41	125	0.42(0.30-0.57)
		<b>heterogeneity</b>		p=0.375

**Supplementary Table 2** - Analysis stratified by time to diagnosis.

	<b>cohorts</b>			
	<b>NOWAC</b>	<b>MCCS</b>	<b>NSHDS</b>	<b>EPIC-HEIDELBERG</b>
<b>number of eligible cases</b>	132	367	245	66
<b>number of cases considered in the analysis*</b>	125*	367*	234*	63
	<b>nested case-control studies</b>			
<b>age at baseline (years)</b>	47 (range: 34 -61)	59 (range: 39 - 70)	55 (range: 29-64)	56 (range: 39-65)
<b>age at diagnosis (years)</b>	56 (range: 47 - 64)	69 (range: 48 - 80)	64 (range: 42-81)	61 (range: 45-70)
<b>time from blood draw to diagnosis (years)</b>	3.88 (range: 0.29 - 7.92)	9.38 (range: 0.01 - 18.67)	9.6 (range: 1.1-17.5)	4.8 (range: 1.1-8.6)
<b>women (N)</b>	250	276	230	22
<b>men (N)</b>	0	458	238	104

**Supplementary Table 3** - Summary of the key characteristics of the study groups.